International Journal of Pharmacy and Pharmaceutical Research (IJPPR)
Volume 32, Issue 3, March 2026 **ijppr.humanjournals.com** ISSN: 2349-7203

Targeted Therapy Approaches in the Management of Non-Small Cell Lung Cancer

Dr.Suresh[1]*, R.Manoj[1], S.Kanagaraj[1], J.Rahamathulla[1], Dr. Neelavni Thangavel[2]

1. Department of Pharmacology, RVS College of Pharmaceutical Sciences, Coimbatore, Tamil Nadu, Affiliated to The Tamil Nadu Dr MGR Medical University, Guindy, Chennai - 600032, Tamil Nadu, India.
2. Department of Pharmaceutical Chemistry, RVS College of Pharmaceutical Sciences, Coimbatore, Tamil Nadu, Affiliated to The Tamil Nadu Dr MGR Medical University, Guindy, Chennai-600032, Tamil Nadu, India.

Received: 18 January 2026 Revised: 30 January 2026 Accepted: 19 February 2026

ABSTRACT

Non-small cell lung cancer (NSCLC) accounts for most lung cancer diagnoses and remains a significant global health challenge. Traditional treatment modalities such as surgery, radiotherapy, and chemotherapy have provided limited survival benefits in advanced disease stages. The identification of molecular drivers involved in tumor initiation and progression has led to the development of targeted therapies that selectively inhibit oncogenic signaling pathways. These treatments have markedly enhanced treatment response, extended progression-free survival, and improved overall quality of life in patients selected based on specific molecular characteristics. This review comprehensively discusses the molecular biology of NSCLC, current targeted therapeutic strategies, clinical applications, resistance mechanisms, safety considerations, and future perspectives.

Keywords : Non-small cell lung cancer; Targeted therapy; Molecular diagnostics; Tyrosine kinase inhibitors; Precision oncology

1. INTRODUCTION

Around 85% of all cases of lung cancer are non small cell lung cancer (NSCLC), making lung cancer the leading cause of cancer-related death worldwide (1).This alarming statistic underscores the critical public health challenge posed by this disease. Unfortunately, Lung cancer is often detected at an advanced stage, which severely limits the effectiveness of curative surgical interventions that might otherwise offer a chance for recovery. Historically, the cornerstone of treatment for advanced NSCLC has been platinum based chemotherapy, a regimen that has been widely utilized for many years. However, the limitations of this approach are evident; its non-specific mechanism of action has resulted in only modest survival benefits for patients, coupled with substantial toxicity that can significantly impair their quality of life (2).

In the last few years, advances in the concerned field of molecular oncology have shed light on the fact that NSCLC is not a uniform disease, but rather a heterogeneous condition driven by various distinct genetic alterations. The development of targeted therapies that specifically interfere with these molecular abnormalities has been made possible by this nuanced understanding. For instance, therapies targeting mutations in the EGFR gene have transformed treatment options for certain subsets of NSCLC patients, leading to marked improvements in outcomes. This progress has ushered In the age of precision medicine, lung cancer treatment, enabling more individualised treatment plans based on the distinct genetic makeup of each patient's tumour (3). As a result, the future of lung cancer treatment appears increasingly hopeful, with ongoing research aimed at identifying new targets and improving existing therapies.

International Journal of Pharmacy and Pharmaceutical Research (IJPPR)
Volume 32, Issue 3, March 2026 ijppr.humanjournals.com ISSN: 2349-7203



Figure 1. Overview of NSCLC types of cancers that develop from the lung's epithelial cells, with three main subtypes: adenocarcinoma, squamous cell carcinoma, and large cell carcinoma

2. Epidemiology and Classification of NSCLC

NSCLC, or non-small cell lung cancer, is divided into three main subtypes: adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Among these, adenocarcinoma stands out as the most prevalent subtype, accounting for a large number of lung cancer cases diagnosed globally. This particular subtype is frequently associated with actionable genetic alterations, which are mutations that can be targeted by specific therapies, thereby offering patients a more personalized treatment approach. Epidemiological studies have indicated that there are notable regional variations in the incidence of NSCLC, which are influenced by a mix of factors of factors including smoking patterns, environmental exposure to carcinogens, and individual genetic susceptibility to the disease (4). For instance, regions with higher smoking rates tend to report elevated instances of squamous cell carcinoma, while areas with lower smoking prevalence may see a rise in adenocarcinoma cases. Furthermore, molecular classification based on driver mutations has become increasingly relevant in the modern clinical landscape, as it directly influences therapeutic decision-making. By identifying specific mutations, oncologists can tailor treatment plans that target these alterations, ultimately improving patient outcomes and survival rates. This evolving understanding of the molecular underpinnings of NSCLC underscores the importance of comprehensive genomic profiling in guiding effective treatment strategies.

3. Molecular Pathogenesis of NSCLC

The molecular pathogenesis of non-small cell lung cancer (NSCLC) is a complex process. It involves the disruption of several signaling pathways that are crucial for important cellular functions, including cell growth, survival, new blood vessel formation, and metastasis. Key oncogenic drivers in this disease include mutations and rearrangements in several critical genes. These genes are EGFR (epidermal growth factor receptor), ALK (anaplastic lymphoma kinase), KRAS (Kirsten rat sarcoma viral oncogene), BRAF (B-Raf proto-oncogene), MET (mesenchymal-epithelial transition factor), RET (rearranged during transfection), and ROS1 (ROS proto-oncogene 1) (5). These genetic changes cause the continuous activation of downstream signaling pathways, especially the PI3K/AKT (phosphoinositide 3-kinase/protein kinase B) and MAPK (mitogen-activated protein kinase) pathways. This activation ultimately leads to uncontrolled cell growth and tumor development.

For example, changes in the EGFR gene often link to sensitivity to certain tyrosine kinase inhibitors, leading to significant clinical responses in patients with NSCLC. Additionally, rearrangements involving the ALK gene have been successfully targeted with crizotinib, showcasing the importance of identifying these genetic changes for personalized treatment strategies. Furthermore, molecular testing utilizing next-generation sequencing has become a standard practice in the clinical management of NSCLC patients (6). This advanced technique not only aids in the identification of actionable targets but also allows for a complete understanding of the tumor's genetic landscape, enabling oncologists to tailor therapies that are more effective and potentially improve patient outcomes. Thus, the integration of molecular diagnostics in the treatment of NSCLC represents a significant advancement in oncology, Emphasizing the need for continuous research and development in this area.

4. Targeted Therapy

4.1 EFGR-Targeted Therapy

EGFR mutations, which are genetic alterations that can drive the development of certain cancers, are most commonly observed in adenocarcinoma, particularly among specific demographics such as non-smokers and Asian populations. This prevalence highlights the importance of understanding the molecular underpinnings of cancer in diverse groups. EGFR tyrosine kinase inhibitors (TKIs) work by competitively blocking ATP binding at the receptor's intracellular domain. This action interrupts the signaling pathways that encourage tumor growth and survival.

First-generation EGFR-TKIs, like gefitinib and erlotinib, have been key in showing better progression-free survival compared to standard chemotherapy treatments. These drugs have changed the treatment options for patients with EGFR mutant lung cancer, providing significant clinical benefits. Moreover, second-generation agents like afatinib have introduced a new level of treatment by providing irreversible inhibition of EGFR and related receptors, which may lead to more sustained therapeutic effects.

In recent developments, the third-generation TKI osimertinib has emerged as the preferred firstline agent due to its remarkable efficacy against T790M resistance mutations, which often arise after initial treatment with first- or second-generation TKIs. Additionally, osimertinib has demonstrated favorable activity within the central nervous system, making it particularly valuable for patients who may develop brain Metastases are a common issue in advanced lung cancer. These improvements in targeted therapies highlight the dynamic nature of lung cancer treatment and the ongoing need for personalized approaches based on genetic profiling (7–9).

4.2 ALK and ROS1 Targeted Therapies

ALK gene rearrangements are found in about 3 to 5 percent of non-small cell lung cancer (NSCLC) cases. These rearrangements are linked to specific clinicopathological features that can affect treatment choices and prognosis. These rearrangements often lead to the production of abnormal ALK proteins, which drive tumor growth. Crizotinib was the first ALK inhibitor approved for clinical use. It represented a major step forward in targeted therapy for patients with ALK-positive NSCLC. However Second- and third-generation inhibitors like alectinib, brigatinib, and lorlatinib have demonstrated superior efficacy in clinical trials, showing not only improved response rates but also enhanced central nervous system penetration, which is crucial as brain metastases are common in this patient population.

Furthermore, ROS1 rearrangements, though rare in comparison to ALK alterations, represent another actionable target in the realm of targeted therapies for lung cancer. These rearrangements have been shown to have high sensitivity to both crizotinib and entrectinib, leading to durable clinical responses in patients. The ability to effectively target these genetic alterations has transformed the treatment landscape for lung cancer, providing options that can lead to major improvements in patient outcomes, such as longer progression-free survival and overall survival rates. As ongoing research continues to uncover additional molecular targets and refine treatment strategies, the importance of genetic testing in NSCLC becomes increasingly evident, underscoring the need for personalized approaches to therapy.

4.3 BRAF and MEK Inhibitors

BRAF V600E mutations occur in a small proportion of patients diagnosed with non-small cell lung cancer (NSCLC), specifically affecting approximately 1-3% of this patient population. These mutations activate the MAPK signaling pathway. This pathway is important for cell growth and survival. The presence of BRAF V600E mutations is significant as they can contribute to the tumorigenic process and influence the development of the disease. Recent studies have shown that combination therapy using BRAF inhibitors like vemurafenib and MEK inhibitors like trametinib has led to better results for these patients. This therapeutic strategy is particularly advantageous as it helps to prevent compensatory pathway activation that can undermine treatment efficacy. By targeting multiple nodes within the signaling pathway, this combination approach not only improves the anti-tumor activity but also reduces the chance of resistance development. Consequently, this dualinhibition strategy represents an important treatment choice for patients with BRAF-mutated NSCLC, offering hope for improved management and survival rates in this specific subgroup of lung cancer patients (13).

4.4 MET and RET Targeted Therapies

MET exon 14 skipping mutations significantly contribute to the activation of ongoing MET signaling pathways. This activation can lead to tumor progression and worse clinical outcomes for patients affected by it. This has prompted the development and utilization of selective MET inhibitors, such as capmatinib and tepotinib, both of which have demonstrated substantial clinical benefit in patients with tumors harboring these mutations. In clinical studies, these inhibitors have shown promising efficacy, leading to improved response rates and overall survival for patients with MET-driven malignancies.

Additionally, RET gene fusions represent another critical target in the landscape of targeted cancer therapies. These genetic alterations can lead to aberrant signaling and tumor growth, making them prime candidates for intervention. Selective inhibitors like selpercatinib and pralsetinib have been developed to specifically target these RET fusions. Clinical trials evaluating these agents have reported high response rates among patients, coupled with manageable toxicity profiles, making them viable options for treatment. As a result, both MET and RET-targeted therapies are at the forefront of precision oncology, offering hope for improved results in patients with certain genetic changes.

4.5 KRAS-Targeted Therapies

KRAS mutations are some of the most common genetic changes found in non-small cell lung cancer (NSCLC). This type makes up the majority of lung cancer cases. Historically, these mutations were seen as unapproachable.primarily due to the unique structure of the KRAS protein, which posed significant challenges for therapeutic intervention. However, recent advancements in cancer treatment have brought about development of KRAS G12C inhibitors include sotorasib and adagrasib. These groundbreaking therapies represent a major change in the treatment approach for patients with NSCLC, offering effective options for those who previously had limited therapeutic choices. For instance, clinical trials have demonstrated that sotorasib can lead to a meaningful reduction in tumor size and improve overall survival rates in patients harboring the KRAS G12C mutation. Similarly, adagrasib has shown promise in achieving durable responses in a substantial proportion of treated patients. This progress not only highlights the importance of targeted therapies but also underscores the potential for improving patient outcomes in a field where options were once scarce (16).

4.6 Anti-Angiogenic Therapy

Tumor angiogenesis plays an important role in the progression of non-small cell lung cancer (NSCLC), which is a leading cause of cancer-related deaths worldwide. This process involves the creation of new blood vessels from existing ones. This is essential for tumor growth and spread. Bevacizumab is a monoclonal antibody that specifically targets vascular endothelial growth factor (VEGF). It effectively stops the formation of blood vessels associated with tumors. By blocking VEGF, Bevacizumab disrupts the supply of nutrients and oxygen to the tumor, which hinders its growth. This therapeutic agent has received approval for use in combination with chemotherapy for patients suffering from severe non-squamous NSCLC, a subtype of lung cancer that does not exhibit squamous cell characteristics. The integration of anti-angiogenic therapy, such as Bevacizumab, into treatment regimens has been shown to contribute significantly to improved disease control, leading to enhanced progression-free survival for patients. Clinical studies have demonstrated that patients receiving this combination therapy often experience a delay in disease advancement, underscoring the importance of targeting angiogenesis in the management of NSCLC (17).

4.7 Mechanisms of Resistance to Targeted Therapy

Acquired resistance is a major and ongoing challenge in targeted therapy for non-small cell lung cancer (NSCLC). This resistance can develop through several mechanisms that make treatment outcomes more complicated. Notably, one of the primary mechanisms is the emergence of secondary mutations within the target gene, which can render previously effective therapies ineffective. For instance, mutations in the EGFR gene may result in resistance against EGFR inhibitors, necessitating a need for alternative treatment approaches. Additionally, the activation of bypass signaling pathways can occur, wherein cancer cells circumvent the targeted pathway by utilizing alternative routes for growth and survival, thereby undermining the efficacy of the targeted agents.

Moreover, histological transformation is another critical factor contributing to resistance; this refers to the process where cancer cells change their characteristics, potentially shifting from a non-small cell type to a more aggressive small cell lung cancer phenotype. Tumor heterogeneity also plays a crucial role, as the presence of diverse cell populations within a single tumor can lead to differential responses to therapy, with some cells surviving and proliferating despite treatment.

To effectively combat these challenges, continuous molecular monitoring of tumor genetics is essential. This involves regularly assessing the genetic landscape of the tumor to detect any emerging resistance mutations. The development of next-generation inhibitors that can target resistant clones or alternative pathways is essential for overcoming treatment resistance and improving patient outcomes. By addressing these complex mechanisms of resistance, we can increase the effectiveness of targeted therapies for NSCLC and ultimately raise survival rates for patients affected by this condition (18).

5. Safety and Adverse Effects

Although targeted therapies are generally better tolerated than conventional chemotherapy, they are associated with unique adverse effect profiles. Common toxicities include dermatological reactions, gastrointestinal disturbances, hepatotoxicity, and cardiotoxicity. Early recognition and appropriate management of adverse effects are critical for ensuring optimal treatment outcomes(19).

6. Future Perspectives and Emerging Strategies

Future research in NSCLC targeted therapy focuses on identifying novel molecular targets, improving combination strategies, and integrating targeted agents with immunotherapy. Advances in liquid biopsy technology and real-time genomic analysis are expected to further enhance personalized treatment approaches.

7. Conclusion

The rise of targeted therapy has changed how we treat Non-Small Cell Lung Cancer (NSCLC). Instead of using a generic cytotoxic approach for everyone, doctors can now provide personalized treatment plans based on the unique molecular profile of a patient's tumor. This shift has brought NSCLC treatment into a new era where genetic drivers, not just cell type, determine the treatment path.

8. REFERENCES

1.Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. CA Cancer J Clin.
2.Herbst RS, Morgensztern D, Boshoff C. The biology and management of non-small cell lung cancer. N Engl J Med.
3.Liu G, Crino L, Felip E. Targeted therapy for non-small cell lung cancer. Semin Respir Crit Care Med.
4.Suster DI, Mino-Kenudson M. Molecular pathology of lung cancer. Arch Med Res.
5.National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Non-Small Cell Lung Cancer.
6.Camidge DR, Doebele RC, Kerr KM. Comparing and contrasting predictive biomarkers for immunotherapy and targeted therapy of NSCLC. Nat Rev Clin Oncol.
7.Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or platinum-pemetrexed in EGFR T790Mpositive lung cancer. N Engl J Med.
8.Soria JC, Ohe Y, Vansteenkiste J, et al. Osimertinib in untreated EGFR-mutated advanced nonsmall-cell lung cancer. N Engl J Med.
9.Shaw AT, Bauer TM, de Marinis F, et al. First-line lorlatinib or crizotinib in advanced ALKpositive lung cancer. N Engl J Med.
10.Drilon A, Siaw JT, Yeh IT, et al. Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. J Clin Oncol.
11.Planchard D, Smit EF, Groen HJM, et al. Dabrafenib plus trametinib in patients with BRAF V600E-mutant metastatic non-small-cell lung cancer. Lancet Oncol.
12.Wolf J, Seto T, Han JY, et al. Capmatinib in MET exon 14-mutated or MET-amplified nonsmall-cell lung cancer. N Engl J Med.
13.Skoulidis F, Li BT, Dy GK, et al. Sotorasib for lung cancers with KRAS G12C mutation. N Engl J Med.
14.Ferrara N, Adamis AP. Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug Discov.
15.Peters S, Camidge DR, Shaw AT, et al. Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer. Ann Oncol.
16.Hanna N, Johnson D, Temin S, et al. Systemic therapy for stage IV non-small-cell lung cancer: ASCO clinical practice guideline update. J Clin Oncol.
17.Remon J, Hendriks LEL, Cardona AF, et al. Liquid biopsy for the management of non-small cell lung cancer. Cancer Treat Rev.
18.Drilon A, Oxnard GR, Tan DSW, et al. Efficacy of selpercatinib in RET fusion-positive nonsmall-cell lung cancer. Nat Med.
19.Riely GJ, Wood KA, Rauh-Adelmann C, et al. Patient-reported outcomes and safety of targeted therapies in NSCLC. Clin Cancer Res.

International Journal of Pharmacy and Pharmaceutical Research (IJPPR)
Volume 32, Issue 3, March 2026 **ijppr.humanjournals.com** ISSN: 2349-7203

How to cite this article:
Dr.Suresh et al. Ijppr.Human, 2026; Vol. 32 (3): 10-16.

Conflict of Interest Statement: All authors have nothing else to disclose.

	Dr.Suresh, Professor, Department of pharamcology, R.V.S College of pharmaceutical sceince, Sulur,Coimbatore, 641402.
	J.Rahamathulla, Department of pharmacology, R.V.S College of pharmaceutical sceince, Sulur,Coimbatore, 641402.
	S.Kanagaraj, Department of pharmacology, R.V.S College of pharmaceutical sceince, Sulur,Coimbatore, 641402.
	R.Manoj, Department of pharmacology, R.V.S College of pharmaceutical sceince, Sulur,Coimbatore, 641402,

Dr. Neelaveni Thangavel
Principal, Department of Pharmaceutical Chemistry.
RVS College of Pharmaceutical Sciences, Sulur, Coimbatore, 641402.